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A TRAF3-NIK module differentially regulates DNA
vs RNA pathways in innate immune signaling
Kislay Parvatiyar1, Jose Pindado1, Anurupa Dev2, Saba Roghiyh Aliyari1, Shivam A. Zaver1, Hoda Gerami1,
Maxime Chapon1, Amir A. Ghaffari1,3, Anant Dhingra1 & Genhong Cheng1,2,4
Detection of viral genomes by the innate immune system elicits an antiviral gene program
mediated by type I interferons (IFNs). While viral RNA and DNA species induce IFN via
separate pathways, the mechanisms by which these pathways are differentially modulated
are unknown. Here we show that the positive regulator of IFN in the RNA pathway, TRAF3,
has an inhibitory function in the DNA pathway. Loss of TRAF3 coincides with increased
expression of the alternative NF-κB-inducing molecule, NIK, which interacts with the DNA
pathway adaptor, STING, to enhance IFN induction. Cells lacking NIK display defective IFN
activation in the DNA pathway due to impaired STING signaling, and NIK-deficient mice are
more susceptible to DNA virus infection. Mechanistically, NIK operates independently from
alternative NF-κB signaling components and instead requires autophosphorylation and oli-
gomerization to activate STING. Thus a previously undescribed pathway for NIK exists in
activating IFN in the DNA pathway.
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Innate immunity provides a critical first step in initiating hostdefense against microbial pathogens. In the innate immuneresponse to viral infections, the induction of type I interferon
(IFN) cytokines, including IFN-β/-α, is fundamental as they elicit
the potent activation of an antiviral cellular gene program that
rapidly culminates in the inhibition of viral replication and
spread1,2.
Activation of IFN is regulated primarily by the interferon
regulatory factor 3 (IRF3) transcription factor that undergoes
phosphorylation-dependent activation by the upstream TANK-
binding kinase 1 (TBK1). Innate immune activation of the TBK1/
IRF3 signaling axis is largely governed by engagement of select
pattern recognition receptors (PRRs) that recognize viral gen-
omes. Certain membrane-bound PRRs can detect viral nucleic
acids on the cell surface or in endosomes while intracellular PRRs
detect viral nucleic acids confined to cytosolic compartments2,3.
These cytosolic PRRs can be categorized by the nucleic acid types
they detect: RNA species, particularly double-stranded RNA
(dsRNA) is sensed by the retinoic acid inducible gene I (RIG-I,
aka DDX58) or melanoma differentiation associated gene 5
(MDA5) helicases, whereas dsDNA species are sensed by cyclic
guanosine adenosine monophosphate synthase (cGAS, aka
MB21D1), DEAD-box helicase 41 (DDX41), or interferon
gamma-inducible protein 16 (IFI16). In the dsRNA-sensing PRR
pathway, signaling to TBK1/IRF3 to activate IFN requires the
mitochondrial adaptor, interferon-β promoter stimulator-1 (IPS-
1, aka MAVS/CARDIF/VISA) (RNA/IPS-1 pathway). Alter-
natively, in the dsDNA-sensing PRR pathway, activation of IFN
via TBK1/IRF3 is conferred via the endoplasmic reticulum
adaptor, stimulator of interferon genes (STING, aka TMEM173/
MPYS/MITA/ERIS) (DNA/STING pathway)2,4–6.
Although extensive studies have focused on the activation and
regulation of the RNA or the DNA pathways, our understanding
of how they are differentially regulated are poorly understood
while the mechanisms that govern how these pathways crosstalk
with each other is unknown. Work by our group and others
previously defined a critical role for tumor necrosis factor (TNF)
receptor-associated factor 3 (TRAF3) in mediating the activation
of IFN in the RNA pathway. Mechanistically, TRAF3 associated
with the RNA pathway adaptor, IPS-1, to drive signal activation
to the TBK1–IRF3 signaling axis7–10. However, the role of TRAF3
in the DNA pathway has not been determined. Here we
demonstrate that TRAF3 plays a direct opposite role in the DNA
pathway, functioning as a negative regulator of DNA virus or
DNA species-mediated activation of the IFN response. TRAF3
licensed the suppression of the alternative nuclear factor (NF)-κB
inducing kinase (NIK, aka MAP3K14), which resulted in
impaired IFN activation in the DNA pathway while displaying a
heightened IFN response in the RNA pathway. NIK associated
with the DNA pathway adaptor, STING, to enhance its activation
via an alternative NF-κB pathway-independent mechanism.
Together, our data describe a unique signaling module (TRAF3/
NIK) that oppositely regulates the same signaling output (IFN) in
a manner dependent on the signaling input (nucleic acid type),
ultimately revealing a novel regulatory crosstalk mechanism
between the RNA and the DNA pathway.
Results
TRAF3 plays opposing roles in regulating IFN in the RNA vs
DNA pathways. TRAF3 functions as a key positive regulator of IFN
in the RNA pathway. We sought to determine whether TRAF3 was
also critical in activating IFN in the DNA pathway. As expected,
murine embryonic fibroblasts (MEFs) lacking TRAF3 displayed
impaired IFN (IFN-β or IFN-α cytokine) production when infected
with the RNA virus, Sendai virus (SeV), or transfected with the
dsRNA mimetic, poly I:C (pI:C), when compared to wild-type (WT)
control MEFs. Surprisingly, Traf3−/− MEFs infected with the DNA
virus, herpes simplex virus 1 (HSV-1), or transfected with dsDNA,
poly dA:dT (B-DNA) or other DNA species, presented a polar
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Fig. 1 The modulators of the alternative NF-κB pathway play a negative regulatory role in the DNA pathway. a, b IFN-β quantification via ELISA from
supernatants collected 24 h postinfection or stimulation of WT and Traf3−/− MEFs infected with Sendai virus (SeV) or herpes simplex virus 1 (HSV-1)
(MOI 0.1) (a) or transfected with poly I:C (100 ng/mL) or B-DNA (500 ng/mL) (b). Data are means ± SEM of one experiment run in duplicates out of 2–3
independent experiments. c Immunoblot analysis of IRF3 activation in WT and Traf3−/− MEF cells infected HSV-1 (MOI 0.1) at the indicated time points.
Results are representative of two independent experiments. d, e Viral titers determined via plaque assay from supernatants of WT and Traf3−/− MEFs
infected with HSV-1 (MOI 0.1) (d) or vesicular stomatitis virus (VSV) (MOI 0.01) (e) analyzed 18, 21, and 24 h postinfection. Data are means ± SEM of one
experiment run in duplicates out of 2–3 independent experiments. f Immunoblot analysis of HSV-1 encoded protein ICP4 in WT and Traf3−/− MEF cells
infected HSV-1 (MOI 0.1) at the indicated time points. Actin serves as a loading control. Results are representative of two independent experiments.
g, h Gene expression levels of IFN-β determined via Q-PCR in WT and Traf2−/−MEFs (g) or in WT and ciap1/2−/−MEFs (h) stimulated with B-DNA (500
ng/mL) for 4 h. Data are means ± SEM of one experiment run in triplicates out of 2–3 independent experiments. p < 0.05 is considered significant
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opposite response, showcasing elevated levels of IFN compared to
the WT MEFs (Fig. 1a, b and Supplementary Figure 1A–B).
IFN activation is primarily dependent on the IRF3 transcrip-
tion factor that requires phosphorylation-dependent activation by
the upstream kinase, TBK1. Traf3−/− MEFs infected with HSV-1
displayed increased levels of TBK1 and IRF3 phosphorylations,
whereas Traf3−/− MEFs infected with SeV displayed reduced
TBK1 and IRF3 phosphorylations when compared to WT MEFs
(Fig. 1c and Supplementary Figure 1C).
In innate antiviral immune pathways, IFN activates a Janus-
activated kinase-signal transducer and activator of transcription
factor (STAT) signaling cascade to initiate the induction of an
antiviral state. Traf3−/− MEFs infected with HSV-1 displayed
increased levels of STAT1 phosphorylation compared to WT
MEFs (Supplementary Figure 1D). Consequently, TRAF3-
deficient MEFs presented with reduced DNA viral loads of
HSV-1 and the murine herpes virus 68 (MHV-68), which was in
contrast to TRAF3-deficient MEFs that presented with increased
RNA viral loads of vesicular stomatitis virus (VSV) in comparison
to WT MEFs (Fig. 1d, e and Supplementary Figure 1E).
Immunoblotting analysis further showed dampened expression
of DNA virus-encoded proteins in Traf3−/− MEFs infected with
HSV-1 (Fig. 1f and Supplementary Figure 1F).
To confirm the DNA pathway-induced levels of the heightened
IFN response displayed in the Traf3−/− MEFs was indeed due to
TRAF3, Traf3−/− MEFs were reconstituted with either empty
vector or a plasmid encoding TRAF3. IFN levels were then
monitored after DNA virus infection. As expected, Traf3−/−
MEFs harboring empty vector plasmid showed elevated IFN
levels after HSV-1 infection compared to WT MEFs. However,
Traf3−/− MEFs transduced with the TRAF3 plasmid showed
decreased IFN expression when infected with HSV-1 (Supple-
mentary Figure 1G–H). As such, Traf3−/− MEFs reconstituted
with TRAF3 displayed viral loads comparable to WT MEFs when
infected with HSV-1 (Supplementary Figure 1I). To further
confirm that TRAF3 functioned as a negative regulator of the
DNA pathway, the DNA-induced IFN response was examined in
bone marrow-derived macrophages (BMDMs) derived from
TRAF3-deficient mice. Similar to Traf3−/− MEFs, Traf3−/−
BMDMs infected with HSV-1 also displayed elevated levels of
IFN when compared to BMDMs derived from WT mice
(Supplementary Figure 1J–K).
TRAF3 functions as a key negative regulator of an alternative
NF-κB signaling pathway where it operates as part of a
multiprotein complex containing TRAF2 and cellular inhibitor
of apoptosis 1 and 2 (cIAP1 and cIAP2, aka BIRC2 and BIRC3)
11,12. We therefore examined whether these other inhibitory
components phenocopied TRAF3 in inhibiting the DNA
pathway. Traf2−/− MEFs showed impaired IFN production in
response to SeV infection or pI:C transfection (Supplementary
Figure 1L–M) compared to WT MEFs. In contrast, B-DNA
transfected or HSV-1-infected Traf2−/− MEFs displayed a
heightened IFN response, similar to that of Traf3−/− MEFs
(Fig. 1g and Supplementary Figure 1N) and consequently
showed increased levels of STAT1 phosphorylation upon DNA
virus infection (Supplementary Figure 1O). Similar to TRAF3,
cIAP1 and cIAP2 have been demonstrated to function as
positive regulators of the RNA pathway13. Consistent with the
TRAF3 and TRAF2 phenotype observed in the DNA pathway,
cIAP1/2 doubly deficient MEFs displayed increased IFN
activation when transfected with B-DNA (Fig. 1h and
Supplementary Figure 1P).
These results uncover a surprising role for TRAF3 and its
alternative NF-κB inhibitory multiprotein complex constituents,
TRAF2, cIAP1, and cIAP2, in positively regulating IFN in the RNA
pathway while negatively regulating IFN in the DNA pathway.
NIK is a positive regulator of the DNA pathway. In most resting
cells, TRAF3, TRAF2, cIAP1, and cIAP2 expression is static as they
cooperate to suppress NIK, a key instigator of alternative NF-κB
signaling14–16. Indeed, cells lacking any of these inhibitory com-
ponents have been shown to display an increase in NIK protein
expression. To determine the physiological relevance of TRAF3 in
the DNA pathway, cells were transduced with B-DNA. Immunoblot
analysis revealed that DNA pathway activation caused a
decrease in TRAF3 levels. Furthermore, the loss of TRAF3
expression was concomitant with an increase in NIK expression in
B-DNA-transduced cells (Fig. 2a). We therefore hypothesized that
the increased levels of IFN presented in the cells lacking TRAF3
when infected with DNA virus or transfected with B-DNA
were imparted by NIK. To test this, Traf3−/− MEFs were
transfected with small interfering RNA (siRNA) targeting NIK.
Indeed, B-DNA-mediated activation of IFN in TRAF3-deficient
MEFs was dampened when NIK was knocked down (Supplemen-
tary Figure 2A).
To verify a role for NIK in facilitating the enhanced IFN
activation phenotype in response to the DNA pathway, cells lacking
NIK were transfected with B-DNA and monitored for IFN
activation. Indeed, NIK-deficient MEFs and BMDMs displayed
defective induction of IFN in response to B-DNA and other DNA
species (Fig. 2b, c and Supplementary Figure 2B–C). BMDMs
lacking NIK also showed impaired IFN induction in response to
infections with HSV-1 and MHV-68, as well as with the
intracellular bacterium, Listeria monocytogenes, known to activate
IFN via the DNA pathway (Fig. 2d and Supplementary Figure 2D)
17,18. As such, the defective IFN responses in the NIK-deficient cells
resulted in higher DNA viral loads compared to infected WT cells
(Fig. 2e, f). In contrast, and consistent with published reports19,
NIK played an opposite role in the RNA pathway, functioning as a
negative regulator of RNA-mediated activation of IFN as NIK-
deficient cells harbored reduced RNA viral loads compared to WT
control cells (Supplementary Figure 2E–F).
To determine whether the impaired IFN activation pre-
sented in the NIK-deficient cells in response to the DNA
pathway was due to dysfunctional IRF3 activation, immuno-
blot analysis was performed. Indeed, NIK-deficient BMDMs
and MEFs displayed reduced IRF3 phosphorylation in
response to B-DNA stimulation when compared to WT
control cells (Fig. 2g and Supplementary Figure 2G–H).
Notably, cells lacking NIK showed no obvious reduction in
expression of key upstream signaling components specific to
the DNA pathway (Supplementary Figure 2I)20,21.
To confirm that the impaired IFN induction in the DNA
pathway as well as the heightened DNA viral levels displayed in
the NIK-deficient cells were in fact imparted by NIK, Nik−/−
MEFs were reconstituted with either empty vector or a plasmid-
expressing NIK followed by transfecting or infecting the cells with
B-DNA or HSV-1, respectively. Indeed, cells lacking NIK that
were reconstituted with NIK showed an increase in IFN
activation in response to B-DNA stimulation and harbored lower
levels of HSV-1 when compared to NIK-deficient cells transduced
with a control empty vector (Supplementary Figure 2J–L).
Taken together, our data indicate that the TRAF3-regulated
protein, NIK, functions as a positive regulator of the DNA
pathway while serving an opposite role in the RNA pathway.
Thus a TRAF3/NIK module differentially controls RNA vs DNA
pathway activation in innate antiviral signaling to IFN.
NIK enhances STING signaling. To elucidate how NIK was
positively regulating the DNA pathway selectively, we hypo-
thesized NIK operated via a signaling component restricted to
the DNA pathway. While multiple PRRs have been described to
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detect DNA species, it is believed that all DNA-dependent
signaling to IFN requires the adaptor STING to facilitate
downstream signal transmission to the IRF3 transcription
factor4,22. Co-immunoprecipitation experiments using epitope-
tagged NIK, STING, and IRF3 in human embryonic kidney
293T (HEK 293T) cells revealed that NIK interacted with
STING as well as IRF3 while confocal analysis showed NIK co-
localized with STING (Fig. 3a and Supplementary Figure 3A).
NIK also associated with STING at the endogenous level
upon B-DNA stimulation (Fig. 3b). Next we wanted to deter-
mine the physiological consequence of the NIK–STING
interaction. Reporter assays revealed that NIK synergized
with STING to increase STING-dependent activation of an
IFN-β luciferase reporter (Fig. 3c). Operating differentially in
the RNA pathway, however, NIK blocked IFN-β activation
mediated by the RNA pathway adaptor, IPS-1 (Supplementary
Figure 3B).
In the DNA pathway, STING undergoes dimerization as a
prerequisite for IFN activation23–25. Ectopic expression of NIK
increased the formation of STING–STING complexes and STING
dimers (Fig. 3d and Supplementary Figure 3C). In contrast, B-
DNA-induced dimerization of STING was impaired in NIK-
deficient cells (Fig. 3e). Recent studies have further indicated
STING forms high-order aggregates upon activation in the DNA
pathway to achieve IFN activation21,26. Our data show that NIK
could also elevate STING aggregation (Supplementary Figure 3C).
In the DNA pathway, activated STING bridges TBK1 with IRF3
to promote IRF3 phosphorylation-dependent activation27. Since
NIK also interacted with IRF3 (Fig. 3a), we wanted to determine
its physiological relevance. Expression of IRF3 or NIK alone led to
minimal activation of the IFN-β luciferase reporter. However,
IFN-β activity was synergistically elevated when IRF3 and NIK
were co-expressed (Supplementary Figure 3D). Accordingly, the
expression of NIK enhanced STING–IRF3 complex formation
(Fig. 3f), while STING–IRF3 or STING–TBK1 complex forma-
tions were compromised in cells lacking NIK (Fig. 3g).
These findings suggest NIK functions as a positive regulator of
the DNA pathway by targeting STING and enhancing its activation
resulting in elevated STING signaling complex formations.
Alternative NF-κB activation heightens DNA pathway signal-
ing. In resting cells, NIK is persistently suppressed by the
TRAF3–TRAF2–cIAP1–cIAP2 inhibitory complex as a mechan-
ism to prevent aberrant activation of the alternative NF-κB sig-
naling pathway. Ligation of select TNF receptor super family
(TNFRSF) members results in the degradation of TRAF3 and
TRAF2, lifting their inhibition of NIK. Likewise, cellular treat-
ment with second mitochondria-derived activator of caspases
(SMAC) mimetics (SM) (a small molecule compound which
mimics the pro-apoptotic SMAC (aka Diablo) protein to antag-
onize cIAP function) also results in the increase of NIK
expression15,28,29. We therefore hypothesized that activation of
the alternative NF-κB signaling pathway by either TNFRSF liga-
tion or SM treatment would also enhance IFN activation in the
DNA pathway due to their abilities to induce NIK expression.
Indeed, MEF cells pre-stimulated with a lymphotoxin beta
receptor agonistic antibody (LT-βR Ab) or SM increased NIK
expression and B-DNA-mediated induction of IFN compared to
untreated cells (Fig. 4a, b and Supplementary Figure 4A). Simi-
larly, SM pretreatment of murine BMDMs, human A549 lung
epithelial cells, or primary human peripheral blood monocytes
(PBMC) led to enhanced IFN activation in the DNA pathway
(Fig. 4c–e and Supplementary Figure 4B). Notably, SM and LT-
βR Ab required NIK as they could not elevate the DNA pathway
IFN response in cells lacking NIK (Supplementary Figure 4C).
Owing to the increase in IFN levels upon LT-βR Ab or SM
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experiments. g Immunoblot analysis of STING phosphorylation (Ser 366) in THP-1 monocytes pretreated with vehicle control (DMSO) or SM (1 μg/mL) for
16 h followed by B-DNA transfection (1 μg/mL) for the indicated time points. Results are representative of two independent experiments. h Immunoblot
analysis of IRF3-STING interactions in WT MEFs pretreated with DMSO or SM (1 μg/mL) for 16 h and subsequently transfected with B-DNA (2 μg/mL) for
the indicated time points. Results are representative of two independent experiments. i Immunoblot analysis of IRF3 and TBK1 activation in A549 cells
pretreated with vehicle control (DMSO) or SM (1 μg/mL) for 16 h followed by B-DNA transfection (2 μg/mL) for 4 h. Results are representative of three
independent experiments. p < 0.05 is considered significant
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stimulation, HSV-1-infected MEF cells displayed lower DNA
viral burdens when compared to untreated control cells (Fig. 4f).
Upon PRR sensing of cytosolic DNA, STING exits the
endoplasmic reticulum and translocates to the Golgi apparatus
and ultimately to perinuclear vesicles where it forms punctate
structures (Supplementary Figure 4D) and assembles with
TBK122,30,31. Imaging flow cytometric analysis indicated that
pretreatment of cells with SM further enhanced B-DNA-elicited
formation of STING puncta (Supplementary Figure 4E–G).
TBK1–STING complex formation results in TBK1 phosphoryla-
tion of STING (Ser 366), which leads to the recruitment of IRF3
to STING and allows for TBK1-dependent phosphorylation of
IRF332. Indeed, SM pretreatment increased and prolonged the
levels of phosphorylated STING (Fig. 4g), resulting in sustained
STING-IRF3 recruitment (Fig. 4h) and subsequently elevated
IRF3 phosphorylation (Fig. 4i and Supplementary Figure 4H).
In DNA pathway signaling, STING is also subjected to
feedback inhibition by various mechanisms including Lysine 48
(K48-linked) ubiquitination, which mediates its proteasomal
degradation33–36. Interestingly, NIK expression dampened the
assembly of K48-linked ubiquitin chains on STING (Supplemen-
tary Figure 4I). In support of this observation, SM pretreatment
further delayed B-DNA-instigated turnover of STING compared
to untreated cells (Supplementary Figure 4J).
Thus, in concert with the DNA pathway, induction of
alternative NF-κB signaling/NIK via TNFRSF ligation or
pharmacological reagents increases IFN activation by enhancing
STING signaling and activation.
NIK operates independently of IKKα/p100 in the DNA path-
way. Our data indicate that NIK positively regulates IFN in the
DNA pathway, which can also be synergized via crosstalk with
the alternative NF-κB pathway. As a critical component of the
alternative NF-κB pathway, NIK signals via inhibitor of kappa B
kinase alpha (IKKα, aka Chuk) to phosphorylate the p100 NF-κB
subunit (aka NFkB2), which leads to its activation14,37–40. We
therefore hypothesized that, in the DNA pathway, NIK would
utilize both its signaling partner, IKKα, and the downstream
substrate, p100, to achieve IFN activation as these downstream
components are also activated in response to B-DNA stimulation
(Supplementary Figure 5A). Surprisingly, IKKα did not mirror
NIK in that IKKα-deficient MEFs displayed an increase in IFN
activation in response to B-DNA (Fig. 5a and Supplementary
Figure 5B). Correspondingly and in contrast to NIK-deficient
MEFs, MEFs lacking IKKα harbored lower DNA viral burdens
after infection (Supplementary Figure 5C–D). To further deline-
ate whether NIK required IKKα in the DNA pathway, IKKα-
deficient MEFs were treated with SM followed by B-DNA
transfection. SM (NIK induced) mediated activation of IFN was
still achieved even in the absence of IKKα, suggesting that IKKα is
dispensable in the DNA pathway (Fig. 5b). Similarly, STING-
dependent activation of IFN was not suppressed in IKKα-
deficient MEFs nor did a NIK mutant that does not interact with
IKKα (NIK Aly) show impaired synergy with STING in activating
IFN (Supplementary Figure 5E–F).
The alternative NF-κB transcription factor component, p100,
was also dispensable in eliciting induction of IFN in the DNA
a
0
4000
8000
12,000
16,000
Mock B-DNA
WT MEF
Ikk–/– MEF
p = 0.002
0
100
200
300
400
Mock B-DNA
b
Ikk–/– MEF SM
Ikk–/– MEF NT
P100–/– MEF SM
P100–/– MEF NT
P100–/– MEF
P100–/–/Traf3–/– MEF
P100–/– MEF
P100–/–/Traf3–/– MEF
p = 0.016
c
0
100
200
300
400
500
Mock B-DNA
WT MEF
p = 0.746
p = 0.007 d
0
1000
2000
3000
4000
5000
Mock B-DNA
p = 0.004
e
H
SV
-1
 (P
fu/
mL
)
p = 0.037
p = 0.016
p = 0.001
Ifn
b 
(fo
ld)
f
NT
SM
p = 0.003
p = 0.0001 g
SM:
B-DNA: +
+
––
– – +
++
+
––
– – +
+
p-IRF3
IRF3
WT
kDa
- 55
- 55
IF
N
-β 
(pg
/m
L)
Ifn
b 
(fo
ld)
Ifn
b 
(fo
ld)
Ifn
b 
(fo
ld)
1×106 20
15
10
5
0
B-DNA: –– + +
1×105
1×104
18 h 21 h 24 h
WT Tbk1–/–
Tbk1–/–
Fig. 5 NIK operates independently of the alternative NF-κB signaling components in the DNA pathway. a, b Q-PCR of IFN-β mRNA levels in WT and Ikkα−/−
MEFs (a) or in Ikkα−/− MEFs pretreated with DMSO (NT) or SM (1 μg/mL) for 16 h (b) and subsequently transfected with B-DNA (500 ng/mL) for 4 h.
Data are means ± SEM of one experiment run in triplicates out of 2–3 independent experiments. c IFN-β ELISA from supernatants of WT, P100−/−, and
P100−/−/Traf3−/− MEFs collected 24 h after B-DNA transfection (500 ng/mL). Data are means ± SEM of one experiment run in duplicates out of two
independent experiments. d Q-PCR of IFN-β mRNA in P100−/− MEFs pretreated with DMSO (NT) or SM (1 μg/mL) for 16 h followed by B-DNA
transfection for 4 h. Data are means ± SEM of one experiment run in triplicates out of two independent experiments. e Viral titers determined via plaque
assay from supernatants of P100−/− and P100−/−/Traf3−/− MEFs infected with HSV-1 (MOI 0.1) at the indicated time points. Data are means ± SEM of
one experiment run in duplicates out of two independent experiments. f Q-PCR of IFN-β mRNA induction in WT and Tbk1−/−MEFs pretreated with DMSO
(NT) or SM (1 μg/mL) for 16 h and subsequently transfected with B-DNA (500 ng/mL) for 4 h. Data are means ± SEM of one experiment run in triplicates
out of three independent experiments. g Immunoblot analysis of IRF3 activation in WT and Tbk1−/− MEFs pretreated with DMSO (NT) or SM (1 μg/mL)
for 16 h and subsequently transfected with B-DNA (2 μg/mL) for 2 h. Results are representative of two independent experiments. p < 0.05 is considered
significant
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05168-7
6 NATURE COMMUNICATIONS |  (2018) 9:2770 | DOI: 10.1038/s41467-018-05168-7 | www.nature.com/naturecommunications
pathway (Supplementary Figure 5B and 5G). However, when NIK
was induced, in doubly deficient Traf3−/−P100−/− MEFs or in
P100−/− MEFs pretreated with SM, elevated IFN levels were
restored, indicating that NIK-dependent activation of IFN did not
require p100 (Fig. 5c, d and Supplementary Figure 5H). Elevated
IFN levels displayed in the Traf3−/−P100−/− MEFs consequently
provided greater protection against DNA viral infection com-
pared to P100−/− MEFs (Fig. 5e).
Our results reveal that NIK activates IFN in a manner
independent of its signaling partner, IKKα, and independent of
the alternative NF-κB transcription co-factor, p100. Since NIK
could also interact with IRF3 and increase its activation (Fig. 3a and
Supplementary Figure 3D), we reasoned that NIK was simply a
direct kinase for IRF3. Induction of NIK via SM pretreatment led to
increased IFN activation and IRF3 phosphorylation in the DNA
pathway. However, cells lacking the upstream IRF3 kinase, TBK1,
showed no elevation in IFN activation or IRF3 phosphorylation
when pretreated with SM (Fig. 5f, g and Supplementary Figure 5I).
Thus our findings indicate that NIK is not a kinase for IRF3 and
activates IFN in the DNA pathway via a mechanism that is separate
from its role in the alternative NF-κB pathway.
NIK requires its kinase function and auto-phosphorylation. To
date, IKKα has been demonstrated to be the only known substrate
for the kinase NIK. However, our data indicates that NIK did not
require IKKα to activate IFN in the DNA pathway. We therefore
hypothesized NIK was operating in a kinase-independent manner
to facilitate STING-dependent signaling. However, IFN-β luci-
ferase reporter assays utilizing a WT and a kinase-dead mutant of
NIK (KK429/430AA) (NIK KD) showed that, while WT NIK
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synergized with STING to enhance IFN activation, the NIK KD
mutant failed to support STING-mediated activation of IFN
(Fig. 6a). Similar findings were observed for IRF3 (Supplementary
Figure 6A). In line with these findings, NIK required its kinase
function to increase STING dimerization or aggregation (Fig. 6b
and Supplementary Figure 6B).
Our data indicate that while NIK activates STING in a manner
independent of its canonical substrates, IKKα/p100, it still
requires its kinase function. However, ectopic co-expression of
NIK with STING, TBK1, or IRF3 did not reveal any obvious shift
in their molecular weights when examined via immunoblotting,
suggesting that those signaling components were not direct
substrates of NIK (Fig. 3d, f). To gain a better understanding for
the necessity of the kinase function of NIK in innate antiviral
signaling pathways, we noted an emerging theme of high-order
protein assembly or oligomerization as a requisite in instigating
IFN activation. For example, RIG-I/MDA5 as well as cGAS PRRs
have been demonstrated to form ligand-induced tetramers and
dimers, respectively41–44. The IPS-1 and STING adaptors facilitate
downstream signal transmission by forming aggregates and/or
dimers24,26,45,46. TBK1 and IRF3 both undergo phosphorylation-
dependent dimerization in order to induce IFN47–51. In
line with this signaling paradigm, we hypothesized that the
substrate for NIK was itself and that NIK required its kinase
function to confer auto-phosphorylation, which would lead to its
subsequent stable dimerization as a mechanism to achieve STING
activation. Indeed, NIK required its kinase function to facilitate
NIK dimerization as a NIK KD mutant failed to self-associate or
oligomerize (Fig. 6c and Supplementary Figure 6C). NIK had
been previously reported to undergo auto-phosphorylation (Thr
561 in mouse, Thr 559 in human) in order to activate IKKα in the
alternative NF-κB pathway52. To determine whether NIK also
underwent auto-phosphorylation in the DNA pathway, we
stimulated human A549 lung epithelial cells with B-DNA in a
timed course experiment. Immunoblotting analysis indicated that
NIK was indeed subjected to Thr 559 phosphorylation in
response to B-DNA (Supplementary Figure 6D). In agreement
with our hypothesis that NIK kinase function is important for
auto-phosphorylation-induced dimerization, a NIK Thr 561
phospho-acceptor mutant also displayed an impaired capacity
to dimerize (Fig. 6c). Consequently, only WT NIK (dimer
competent) could increase STING- and IRF3-dependent activa-
tion of IFN, whereas the NIK T561A mutant (dimer incompe-
tent) could not (Fig. 6a and Supplementary Figure 6A). However,
when the NIK T561A mutant (which has intact kinase function)
was co-expressed with the NIK KD mutant (which is competent
in undergoing Thr 561 phosphorylation), STING-mediated
activation of IFN was remediated, further suggesting that the
ability of NIK to phosphorylate and accept phosphorylation is
essential in enhancing STING activation (Supplementary Figure
6E). The crucial role of phosphorylation-dependent dimerization
of NIK was further demonstrated as it was revealed that the NIK
T561A mutant could not promote the formation of STING
dimers nor enhance the formation of STING–IRF3 complexes
(Fig. 6b, d). Mechanistically, the oligomeric conformation of NIK
favored its ability to activate IFN via STING as both the KD and
phospho-acceptor mutant of NIK were defective in interacting
with STING (Fig. 6e). Together, these results uncover a critical
role for NIK kinase function and self-phosphorylation, under-
scoring the essential role of protein oligomerization in driving
signal transduction events.
NIK plays an essential role in restricting DNA virus infection
in vivo. Our data show that, in cells lacking NIK, IFN induction
in response to DNA viral infections or B-DNA stimulation is
impaired, resulting in the failure to control DNA virus replica-
tion. To determine the physiological relevance of NIK in response
to DNA virus infection, WT and NIK-deficient mice were
infected with HSV-1 and monitored for loss in body weight.
While most of the WT mice survived the HSV-1 challenge, all of
the mice lacking NIK displayed a heightened sensitivity to HSV-1,
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presenting with lower survival rates and increased weight loss
(Fig. 7a and Supplementary Figure 7A–B). As these findings
highlight the critical role of NIK in conferring host defense
against DNA viral infections in vivo, we reasoned that elevating
expression of NIK via pharmacological application with SMAC
mimetics could also inhibit DNA virus replication in vivo. In an
HSV-1 vaginal infection model, female mice administered with
SM followed by intravaginal challenge with HSV-1 harbored
reduced viral titers in comparison to untreated infected mice
(Fig. 7b). Likewise, administration of SM resulted in lowered viral
titers of HSV-1 in the spleens of SM-treated mice compared to
those of untreated mice (Fig. 7c). Lastly, utilizing in vivo biolu-
minescence imaging, we found that administration of SM further
enhanced the clearance of HSV-1 compared to matched animals
that were not treated (Fig. 7d). Together these data indicate a
critical in vivo role for NIK and support a therapeutic potential
for SMs in controlling DNA virus infections.
Discussion
Although viral infections trigger the innate immune induction of
IFN, it is becoming increasingly clear that the mode of IFN
activation is dependent upon the PRR type that is engaged.
Indeed, cytosolic detection of RNA virus genomes or RNA species
by the RIG-I like helicases activates IFN via the IPS-1 adaptor
(RNA pathway), while cytosolic sensing of DNA virus genomes
or DNA species by the DDX41 helicase, cGAS, or IFI16 activates
IFN utilizing the STING adaptor (DNA pathway). However,
additional mechanisms that define how these pathways are
separately or differentially modulated are largely uncharacterized.
Previous studies demonstrated that signaling in the RNA pathway
required TRAF3 to facilitate IFN activation. Our current work
shows that TRAF3 surprisingly plays a direct opposite role in the
DNA pathway where it functions to inhibit IFN activation.
TRAF3 exists as part of a multiprotein complex containing
TRAF2, cIAP1, and cIAP2 that function in restricting the acti-
vation of the alternative NF-κB pathway11,12. We found that, like
TRAF3, TRAF2 also played an important role in positively reg-
ulating the RNA pathway and suppressing the DNA pathway.
While the cIAP1 and cIAP2 components have been previously
shown to mediate IFN activation in the RNA pathway13, our
results indicating that they inhibit the DNA pathway is consistent
with the phenotype observed with their interacting partners,
TRAF3 and TRAF2. Therefore, IFN activation in the RNA vs. the
DNA pathway is regulated both positively and negatively,
respectively, by the modulators of the alternative NF-κB signaling
pathway. In this alternative NF-κB pathway, TRAF3, TRAF2,
cIAP1, and cIAP2 cooperate to promote the persistent degrada-
tion of the alternative NF-κB inducing kinase, NIK. A recent
study reported that NIK serves as a negative regulator of IFN in
the RNA pathway19. These findings align with our observation
that cells lacking the NIK inhibitors, TRAF3, TRAF2, cIAP1, or
cIAP2, fail to induce a robust IFN response in the RNA pathway.
Thus TRAF3/TRAF2/cIAP1/cIAP2 may function via a two-
pronged mechanism in the RNA pathway where they operate as
(1) adaptor molecules to mediate downstream signal transmission
to IFN and as (2) inhibitors of the inhibitor, NIK28. Accordingly,
work by other groups examining feedback inhibition have shown
that TRAF3 is subjected to degradation to terminate RNA
pathway signaling, which coincides with NIK accumulation53.
Our findings uncover a similar phenomenon in the DNA path-
way where the abundance of TRAF3 is reduced during signaling
with the concomitant accumulation of NIK. This also suggests a
two-pronged mechanism of regulation in the DNA pathway
where the suppressive role of TRAF3 as a steady state inhibitor is
lifted, allowing for the activating role of NIK to come into play.
Given the relatively slow kinetics of TRAF3 turnover and NIK
accumulation in the DNA pathway, it may be plausible that NIK
functions to sustain IFN activation while playing a less prominent
role in immediate or early DNA PRR signaling. Indeed, the role of
NIK in inducing IFN or in maintaining STING complexes were
markedly noticeable at later time points. Furthermore, our data
showcased a delayed interaction between NIK and the DNA
signaling adaptor, STING. However, it should be noted that there
are technical limitations in detecting accumulated NIK (via
immunoblotting using current commercially available antibodies)
whose expression levels are typically low in different cell types
even upon activation of alternative NF-κB or cytosolic DNA-
sensing pathways. To this end, the deficiency in IFN activation or
the inability of STING to optimally dimerize upon B-DNA sti-
mulation in cells lacking NIK was still apparent at earlier time
points even though NIK protein was not easily detected. Thus a
second, more likely possibility is that NIK may play a more
prominent role in early STING activation, driving later-stage
STING signaling.
During end-stage signaling in the DNA pathway, STING has
also been reported to undergo feedback inhibition via K48-linked
ubiquitination-mediated proteasomal degradation as a regulatory
mechanism to terminate excessive IFN activation33–35. As our
data indicate that NIK expression suppresses the delivery of K48-
linked ubiquitin chains onto STING and enhances STING sta-
bility, it is possible that NIK may further play a role in restricting
the interaction between potential E3 ubiquitin ligases that target
STING for degradation. Alternatively, NIK could be recruiting
de-ubiquitinating enzymes that de-conjugate K48-linked ubiqui-
tin chains from STING36,54. It has been shown that inactive
rhomboid protein 2 (iRhom2) also enhances DNA pathway
activation via a two-pronged mechanism by facilitating STING
trafficking from the endoplasmic reticulum to perinuclear vesicles
and by recruiting the K48-linked de-ubiquitinating enzyme,
eukaryotic translation initiation factor 3 subunit F (EIF3F, aka
EIF3S5), to enhance STING stability36. However, iRhom2 func-
tion is not restricted to the DNA pathway as it was recently
demonstrated that it also enhanced IPS-1 stability to increase
RNA pathway signaling55. Although iRhom2 functions as a
positive regulator of both the DNA and RNA pathways, NIK
selectively functions to positively regulate the DNA pathway
while serving as a negative regulator of the RNA pathway.
Nevertheless, further studies will be necessary to determine
whether NIK cooperates with iRhom2/EIF3F to modulate STING
function in the DNA pathway.
The critical role of NIK was further exemplified by the capacity
of the alternative NF-κB pathway to crosstalk with the DNA
pathway. Interestingly, while NIK-mediated inhibition of the
RNA pathway was shown to require alternative NF-κB pathway
signaling components19, our data indicated NIK activates the
DNA pathway in an alternative NF-κB pathway-independent
manner. We found that neither the classical NIK substrate and
signaling partner, IKKα, nor its downstream alternative NF-κB
transcription co-factor precursor, p100, were essential in sup-
porting IFN activation in the DNA pathway. Unexpectedly, and
in contrast to NIK-deficient cells, cells lacking IKKα displayed
even greater levels of IFN and consequently harbored lower DNA
virus loads. In alternative NF-κB signaling, NIK phosphorylates
IKKα that leads to the activation of its kinase function and
confers its ability to phosphorylate p100 to ultimately yield the
formation of an unrestrained, competent transcription factor
complex. In a negative feedback loop, the activated IKKα also
phosphorylates NIK at a C-terminal cluster consisting of Ser 809,
812, and 815, promoting its degradation in a TRAF3/TRAF2/
cIAP1/cIAP2-independent manner. As such, cells lacking IKKα
fail to degrade accumulated NIK56,57. Thus both the steady-state
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inhibitors as well as the feedback inhibitor of NIK inhibit IFN
activation in the DNA pathway. Importantly, our findings reveal
a new, previously undescribed pathway for NIK that is separate
from its role in the alternative NF-κB pathway, in facilitating IFN
activation in innate antiviral immune signaling.
In addition to NIK enhancing STING activation, our data
showed that ectopic expression of NIK with IRF3 also resulted in
the synergistic activation of IFN. Although NIK interacted with
IRF3, our results revealed that NIK was not a kinase for IRF3 and
confirmed that TBK1 was essential in phosphorylating IRF3 in
the DNA pathway58,59. Nevertheless, since IRF3 is a shared
component in both the DNA/STING and RNA/IPS-1 pathways,
we found it curious as to how NIK supported IRF3 activation as
opposed to inhibition when co-expressed with IRF3. In the RNA
pathway, the IPS-1 adaptor functions to connect the upstream
RIG-I or MDA5 PRRs with TRAF310. This is different in the
DNA pathway where it is believed that the STING adaptor
operates further downstream, bridging the interaction between
TBK1 and IRF327. Alternatively, new studies further indicate that
phosphorylated IPS-1 can also recruit IRF332. Additional
experiments examining how NIK affects IPS-1 at the post-
translational level may reveal how NIK negatively regulates the
RNA/IPS-1 pathway. Given that NIK plays a role in maintaining
or enhancing STING complex formations including those com-
plexes containing STING/TBK1/IRF3, it is possible that NIK
overexpression potentiated the basal activation of endogenous
STING, facilitating the recruitment of TBK1 with the ectopically
expressed IRF3 to drive IFN activation. NIK is also known to
interact with TBK1, also a shared component in both the RNA
and DNA signaling pathways. Interestingly, it was recently
reported that TBK1 played a key regulatory role in the alternative
NF-κB pathway where it phosphorylated NIK at Ser 862 causing
its degradation and the termination NF-κB signaling60. Although
reminiscent of the modulatory role of IKKα in the alternative NF-
κB pathway57, the potential TBK1-NIK regulatory mechanisms in
the DNA pathway will require further investigation.
A common theme in multiple signal transduction pathways is
of protein phosphorylation and oligomerization. Indeed, the RNA
sensors RIG-I and MDA5 have been demonstrated to form tet-
ramers while the cGAS or IFI16 DNA sensors form dimers or
filamentous-like aggregates upon ligand binding. The IPS-1 and
STING adaptors are further subjected to phosphorylation-
dependent aggregation and/or dimerization to facilitate down-
stream signal transmission. Similarly, both the TBK1 kinase and
IRF3 transcription factor undergo dimerization in a
phosphorylation-dependent manner to activate IFN61,62.
Although the downstream substrate of NIK, IKKα, was not
required in the DNA pathway, the kinase function of NIK was
nevertheless revealed to be critical in activating the IFN response.
We did not find STING, TBK1, nor IRF3 to be the obvious
substrates for NIK; however, our data suggested that the kinase
activity of NIK was essential in supporting its ability to self-
associate or oligomerize. Consequently, a KD mutant of NIK
failed to interact with STING and thus could not promote its
activation. Several kinases including TBK1 have been reported to
undergo auto- or trans-phosphorylation in order to achieve a
stable dimeric conformation that confers optimal signaling cap-
abilities49. Seminal studies with NIK uncovered that key residues
in its kinase domain were important in positively regulating its
ability to activate the alternative NF-κB pathway. Indeed, Thr 561
(Thr 559 in human), located within the activation loop of NIK’s
kinase domain, was demonstrated to be an important phospho-
acceptor site and Ala substitution (T561A) failed to induce IKKα
activity and subsequent NF-κB activation52. In support of a
phosphorylation-mediated oligomerization theme in innate sig-
naling, the NIK phospho-acceptor mutant, behaving similarly to
the KD NIK mutant, was compromised in forming competent
dimers. As such, the interaction between NIK KD or NIK T561A
and STING was much weaker compared to NIK WT, explaining
its impaired ability to activate STING or facilitate STING com-
plex formations. These mechanistic findings highlight and further
support the essential role of protein oligomerization as a
mechanism to drive signal transduction pathways.
In the clinic, IFN therapies are widely used to treat multiple
viral infections63,64. Interestingly, the alternative NF-κB pathway
plays an important synergistic role in crosstalking with the DNA
pathway. Indeed, previous works found a link between the
alternative NF-κB pathway and DNA virus-induced activation of
IFN65. Our results revealed and defined the specific role of the
alternative NF-κB inducing kinase, NIK in the DNA pathway
and further elucidated the mechanism by which it facilitates host
defense against DNA virus infections. The elevation of NIK via
ligands that activate TNF superfamily of receptors or by admin-
istration of SMAC mimetics have therapeutic potential in ele-
vating the host IFN response as animals that were pretreated with
SMAC mimetics followed by HSV-1 challenge presented with
lower viral loads compared to non-treated infected animals.
Future studies will be necessary to determine the therapeutic
applications of SMAC mimetics in combating DNA virus
infections.
In summary, we have identified a unique phenomenon where
the same molecule(s) functions to oppositely regulate the host
IFN pathway in a manner that depends on the nucleic acid type
detected. We also uncover a key component of the alternative NF-
κB pathway that operates in a separate, alternative NF-κB-
independent fashion to activate IFN in the DNA pathway. Our
findings further speak of the importance of protein oligomer-
ization in potentiating signal transduction events in innate anti-
viral immunity. Lastly, our work lends to a conceptual framework
in developing potential therapeutic applications in targeting
certain viral infections.
Methods
Mice and cell culture. Generation of Traf3−/−, Nfkb2−/−, Traf3−/−Nfkb2−/−, and
Map3K14−/− mice were previously described12,66,67. All mice were maintained and
bred in specific pathogen-free conditions at the University of California, Los
Angeles, and experiments were performed within the parameters of the protocol
approved by the Animal Research Committee. Traf2−/− MEFs were a kind gift
from Wen-Chen Yeh (University of Toronto). Sting−/− MEFs stably reconstituted
with STING-GFP were kindly provided by Nan Yan (University of Texas South-
western Medical Center). Chuk−/−, Tbk1−/−, and Birc2−/−Birc3−/− MEFs were
previously reported12,57,59. HEK 293T cells, A549 cells, and THP-1 monoctyes
were from American Type Culture Collection (ATCC). BMDMs were harvested
from the femurs and tibias of 6–8-week-old mice and differentiated for 7 days in
Dulbecco’s modified Eagle’s medium (DMEM; Mediatech Inc.) containing 10%
fetal bovine serum (FBS) and macrophages colony-stimulating factor. HEK
293T cells, A549 cells, and MEFs were cultured in DMEM supplemented with 5%
FBS and 1% penicillin/streptomycin. THP-1 monocytes were cultured in RPMI-
1640 (Mediatech Inc.) supplemented with 10% FBS and 0.05 mM 2-
mercaptoethanol.
Reagents. Poly (I:C), poly (dA:dT), ISD, and cGAMP were purchased from
Invivogen. Calf thymus DNA was purchased from Sigma. Vaccinia virus DNA was
purchased from ATCC. Cell transfections were performed using Lipofectamine
2000 while siRNA targeting NIK (Bioneer) was transfected using Lipofectamine
RNAi Max (Invitrogen). SMAC mimetic (NVP-LCL161_NX-g) was generously
provided by Xiaodong Wang (University of Texas Southwestern Medical Center).
IFN-α4 and IFN-β enzyme-linked immunosorbent assay (ELISA) kits were
obtained from PBL Biomedical Laboratories; ELISAs were performed according to
the manufacturer’s recommended protocols. Lymphotoxin beta receptor agonist
antibody was purchased from Alexis Biochemicals. Antibodies were obtained from
the following companies: STING, IRF3, NIK, TBK1, TRAF2, cIAP1, IKKα, p100,
cGAS, β-Actin, phospho-STING (S366), phospho-IRF3 (S396), phospho-TBK1
(S172), phospho-IKKα (S176), and phospho-STAT1 (Y701) (Cell Signaling); Flag,
β-tubulin (Sigma Aldrich); STAT1, HSV-1 ICP4, HSP90, TRAF3, cIAP2, phospho-
NIK (T559), Myc, HA (Santa Cruz Biotechnology); HSV-1 glycoprotein D
(Abcam); and ZDHHC1 (ThermoFisher). Plasmids encoding TRAF3, NIK, IRF3,
STING, IPS-1, TBK1, and K48 only ubiquitin have been described
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elsewhere10,12,17,57. NIK Aly, KD, and T561A mutants were generated using the
Quikchange Site-Directed Mutagenesis Kit (Agilent).
Immunoassays. For immunoblot analysis, cells were harvested in ice-cold NP-40
lysis buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40)
supplemented with complete protease inhibitors (Roche). For immunoprecipita-
tion experiments, precleared lysates from transfected or stimulated cells were
incubated overnight with appropriate antibodies at 4 °C followed by the addition of
protein A agarose beads (Roche) for 4 h at 4 °C. Captured protein complexes were
washed three times with NP-40 lysis buffer containing 250 mM NaCl and then
eluted with 2× Laemmli sample buffer (Bio-Rad) containing β-mercaptoethanol.
Samples were boiled at 95 °C for 5 min followed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS PAGE) and immunoblotting. For semi-
native SDS PAGE, whole-cell lysates were mixed with 2× native sample buffer
(65.8 mM Tris-Cl pH 6.8, 40% glycerol, 0.01% bromophenol blue) without β-
mercaptoethanol and were run on SDS gels without boiling. For semi-denaturating
detergent agarose gel electrophoresis, lysates were separated on 1.5% agarose gels
followed by immunoblotting as described. For detecting STING ubiquitination,
immunoprecipitates were subjected to additional washes containing 1M urea as
previously described68. Proteins were detected via enhanced chemiluminescence
(Pierce). Uncropped immunoblotting data are included in Supplementary Figure 8.
Virus infections and assays. VSV (Indiana Serotype) expressing green fluorescent
protein (GFP) was a kind gift from Glen Barber (University of Miami School of
Medicine). HSV-1 and KOS strain expressing GFP in frame with the ICP0 protein
between amino acids 104 and 105 was generously provided by William Halford
(Southern Illinois University School of Medicine). HSV-1, F strain expressing GFP,
and firefly luciferase was kindly provided by Chunfu Zheng (Wuhan Institute of
Virology, Chinese Academy of Sciences). Creation of an MHV-68 virus expressing
luciferase under an M3 promoter (M3FL) was previously described. SeV (Cantell
strain, VR-907) was purchased from ATCC. Viral titers were determined using
standard plaque assays with Vero cells. Virally infected GFP-positive cells were
determined using standard flow cytometric analysis while virally infected luciferase
harboring cells were detected via a luminometer. For survival assays, sex- and age-
matched WT and NIK-deficient mice were anesthetized by isoflurane and infected
with 1 × 109 plaque-forming units (Pfu) HSV-1 via retro-orbital injection. Animal
weight was monitored daily and mice that lost >20% of their initial weight or those
that showed signs of morbidity were euthanized according to UCLA approved
protocols. For the HSV-1 intra-vaginal model of infection in WT C57/B6 mice,
female mice received a 1 mg subcutaneous injection of Medroxyprogesterone
(Sicor), 48 h prior to infection. Twenty four hours prior to infection, mice were
anesthetized using an intraperitoneal (IP) injection of ketamin/xylazine and were
administered 0.016 mg of SMAC mimetic in 5% dimethyl sulfoxide intravaginally
using a 20 μL pipet. On day 0, mice were re-treated with SMAC mimetic and 4 h
later infected with 2.9 × 107 Pfu/mouse of HSV-1 strain KOS (ATCC). Twenty four
hours later, mice were anesthetized with isoflurane on day 1 to measure vaginal
virus titers by vaginal cavity lavage and subsequently re-treated with SMAC
mimetic. On days 2 and 3, mice were similarly anesthetized with isoflurane prior to
collection of vaginal lavage samples. For in vivo bioluminescent infection and
imaging, WT C57/B6 mice were first anaesthetized by IP with 200 mg/kg ketamine,
4 mg/kg xylazine in phosphate-buffered saline (PBS). HSV-1 GFP Luc (500 pfu) in
200 uL of PBS was administered by IP. On day 3 following infection, mice were
imaged using the in vivo imaging system (IVIS, Xenogen). Briefly, mice were
anesthetized with isoflurane and administered 3 mg D-luciferin/mouse by IP prior
to imaging. Grayscale photographs and color images of imaged mice were super-
imposed with LivingImage (Xenogen) and Igor (Wavemetrics) programs. The mice
were imaged on dorsal, ventral, right, and left side until the maximal luminescence
passed. The peak intensity of average and maximum photon flux value was mea-
sured for each mouse at every angle and expressed as photons/sec/cm2/steradian.
These values were averaged for each group of mice.
Quantitative PCR (Q-PCR). RNA was isolated using TRIzol reagent (Invitrogen)
and converted to cDNA using iScript (Bio-Rad). Q-PCR analysis was performed
using the iCycler thermocycler. Transcript abundance was first normalized to that
of mRNA encoding the ribosomal protein, L32 for murine cells (MEFs or
BMDMs), or the ribosomal protein, 36B4 for human cells (A549 and PBMC) and
then normalized against values for unstimulated or uninfected controls. Primer
sequences are as follows: murine IFNb Fwd AGCTCCAAGAAAGGACGAACAT,
Rev GCCCTGTAGGTGAGGTTGATCT; human IFNb Fwd TGTGGCAATT_G
AATGGGAGGCTTGA, Rev CGGCGTCCTCCTTCTGGAACTG; L32 Fwd
AAGCGAAACTGGCGGAAAC, Rev TAACCGATGTTGGGCATCAG; and 36B4
Fwd TCGAACACCTGCTGGATGAC, Rev CCACGCTGCTGAACATGCT.
Luciferase assays. Cells were transfected with the specified constructs, along with
a Firefly luciferase pGL2-basic reporter plasmid and Renilla luciferase for nor-
malization. Cells were lysed on ice in 1× passive lysis buffer and luciferase values
were quantified on a luminometer using a Dual Luciferase Assay System Kit
(Promega).
Immunofluorescence. HEK 293T cells were transfected with HA-STING and
Myc-NIK expression vectors. After overnight culture, cells were fixed with 4%
paraformaldehyde. Cells were permeabilized with 0.3% Triton-X 100 in PBS and
non-specific antibody binding was blocked with 10% Goat and Donkey serum.
Cells were then stained with Mouse anti-Myc antibody (Santa Cruz Biotechnology
SC-40) and Rabbit anti-HA antibody (Santa Cruz Biotechnology SC-805) diluted 1/
50 in 0.1% Triton-X 100, 1% bovine serum albumin (BSA), and in PBS at 4 °C
overnight. Cells were then stained with Goat anti-mouse Dylight-649 (Biolegend
405312) and Donkey anti-rabbit Dylight-488 (Biolegend 406404) diluted 1/100 in
0.1% Triton-X 100, 1% BSA, and in PBS at room temperature for 1 h. Slides were
mounted with ProLong Gold antifade with 4,6-diamidino-2-phenylindole (Ther-
moFisher Scientific). Staining specificity was confirmed by the absence of signal in
empty vector-transfected cells. Images were acquired on a Leica TCS SP5 II AOBS
confocal microscope at the UCLA MIMG microscopy core facility. Images were
analyzed using the Fiji distribution of the ImageJ software69.
Imaging flow cytometry. Sting−/− MEFs stably expressing STING-GFP were
stimulated for 0, 30, 60, or 120 min with 500 ng/mL B-DNA. Cells were then
trypsinized and fixed for 15 min at room temperature in 2% paraformaldehyde.
Cells were acquired on an ImagestreamX Mark II imaging flow cytometer at the
UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research Flow
Cytometry Core Facility. The acquired events were analyzed using the IDEAS
software (EMD Millipore). Cells were separated based on the puncta detection in
the STING-GFP channel using the spot wizard function. Events with a high
number of puncta were determined to be activated cells based on previous
immunofluorescence staining.
Statistical analysis. Statistical significance for ELISA, Q-PCR, luciferase reporter
assay, plaque assay, flow cytometry (for detecting viral load), and imaging flow
cytometry (for detecting STING translocation/puncta formation) was determined
via Student’s t test. Statistical significance in examining survival among WT and
Nik−/−mice was performed via the Log-rank (Mantel–Cox) test. A p value of <0.05
is considered statistically significant.
Data availability. The data that support the findings of this study are available
from the corresponding author upon request.
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